Funder: Cystic Fibrosis Foundation
Due Dates: November 15, 2026 (Presubmission approval) | December 15, 2026, 5:00 p.m. ET (Full application)
Funding Amounts: Up to $1,000,000 in direct costs annually for up to three years, plus 12% indirect costs
Summary: Supports collaborative research advancing CFTR gene repair, replacement, and delivery technologies for new cystic fibrosis therapies.
Key Information: Programs must include two to four related sub-projects, each led by a separate independent investigator.
Description
The Cystic Fibrosis Foundation’s Path to a Cure Collaborative Research Grant supports integrated research programs developing new therapies or therapeutic strategies, emphasizing delivery of CFTR gene repair and replacement technologies to human epithelia. It addresses unmet needs among people whose CFTR variants do not respond to modulators, produce insufficient protein for correction, or prevent protein synthesis.
Projects should use ambitious, cutting-edge approaches to restore CFTR function. Priorities include cellular targets for nucleotide-based therapies, nucleic acid formulations and viral or non-viral delivery vehicles, pulmonary cell types and lung regions requiring treatment, cellular barriers to delivery, and the effects and durability of genetic manipulation. Collaborations bringing new investigators and technologies into CF research receive highest priority. Multi-institution teams are encouraged, but investigators may share an institution.
